PROMIS NEUROSCIENCES INC. Financing Cash Flow
PROMIS NEUROSCIENCES INC. (PMN) reported Financing Cash Flow of $70.08 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $70.08M.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was -$1.00, a 100.00% decline year-over-year.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for the quarter ending 2024-12-31 was $470.00K.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for fiscal 2025 was $20.94M, a 24.86% decline from fiscal 2024.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for fiscal 2024 was $27.88M, a 57.06% increase from fiscal 2023.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for fiscal 2023 was $17.75M, a 173.28% increase from fiscal 2022.
- PROMIS NEUROSCIENCES INC. net cash provided by (used in) financing activities for fiscal 2022 was $6.49M, a 74.55% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $70.08M 10-Q · filed 2026-08-13 | $70.08M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2026-03-31 | $70.08M 10-Q · filed 2026-05-12 | $70.08M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $20.94M 10-K · filed 2026-03-25 | ||
| 2025-09-30 | $20.94M 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | $470.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $27.69M derived: sum of 2 quarters · filed 2026-03-25 | $27.69M derived: sum of 3 quarters · filed 2026-03-25 | $27.88M 10-K · filed 2026-03-25 |
| 2024-09-30 | $27.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $27.22M derived: sum of 2 quarters · filed 2025-11-12 | $27.41M 10-Q · filed 2025-11-12 | $26.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $190.27K 10-Q · filed 2025-08-13 | -$320.34K derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $190.27K 10-Q · filed 2025-05-12 | -$320.34K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$510.61K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.75M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $18.26M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $6.49M 10-K · filed 2024-04-01 | |||
| 2021-12-31 | $445.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $18.64M derived: sum of 2 quarters · filed 2023-03-08 | $25.52M 10-K · filed 2023-03-08 | |
| 2021-09-30 | $18.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $25.52M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $6.88M 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |